Multi-Leu peptide (triacetate)

Multi-Leu peptide (ML-peptide) triacetate is a potent inhibitor of PACE4 (Ki=22 nM) . Multi-Leu peptide triacetate can competitively bind to the active site of PACE4 by simulating the substrate sequence of PACE4, thereby inhibiting its catalytic activity. Multi-Leu peptide triacetate can be used to study the specific mechanism of PACE4 in the development of prostate cancer[1].

Product Specifications

Product Name Alternative

ML-peptide, Multi-Leucine (ML) -peptide (triacetate)

UNSPSC

12352209

Target

Autophagy

Related Pathways

Autophagy

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Purity

98.64

Smiles

O=C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N)=O)=O)=O)=O)=O)=O)=O)=O)C.CC(O)=O.CC(O)=O.CC(O)=O

Molecular Formula

C55H106N16O15

Molecular Weight

1231.53

References & Citations

[1]Łepek T, et al. Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations[J]. European journal of cell biology, 2017, 96 (5) : 476-485.